Connect your AI

Kymera Therapeutics KYMR Price / sales

Price / sales at other companies

PfizerPFE

2.5×+0.2×

Johnson & JohnsonJNJ

6.1×+1.6×

Regeneron PharmaceuticalsREGN

5.5×+0.6×

ImmunityBio, Inc.IBRX

56.2×-26.1×

Krystal Biotech, Inc.KRYS

18.1×+2.5×

Protagonist TherapeuticsPTGX

90.8×+76.5×

Other financials

Income statement

Revenue$34.4M+55.5%

Operating income-$84.2M-13.1%

Net income-$69.2M-5.6%

EPS (diluted)-$0.71+13.4%

Balance sheet

Cash & equivalents$144.1M+60.2%

Total debt$82.2M-6.5%

Total equity$1.5B+95.8%

Total assets$1.7B+81.7%

Cash flow

Operating cash flow-$88.8M-12.2%

CapEx$434.0K-7.1%

Free cash flow-$89.3M-12.1%

Valuation

Market cap$7.44B+283%

Enterprise value$7.38B+280%

Profitability

Operating margin-697.7%+635pp

Net margin-612%+602pp

FCF margin-474%+92.4pp

Returns & leverage

Return on equity-27.1%-3.7pp

Debt / equity0.1×-0.1×

Current ratio10.8×+2.3×

Where this comes from

Calculated from Kymera Therapeutics’s reported figures.

market cap/total revenue=132.1×

Based on the most recent quarter.

The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kymera Therapeutics's price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Kymera Therapeutics's price / sales?: Kymera Therapeutics (KYMR) reported price / sales of 132.1× in Q1 2026.
How has Kymera Therapeutics's price / sales changed year-over-year?: Kymera Therapeutics's price / sales increased by 337.6% year-over-year, from 30.2× to 132.1×.
What is the long-term trend for Kymera Therapeutics's price / sales?: Over 5 years (2020 to 2025), Kymera Therapeutics's price / sales has grown at a 14.3% compound annual growth rate (CAGR), from 81.3× to 158.8×.
What does price / sales mean?: Market capitalization at the quarter end divided by trailing-twelve-month revenue. The price the market pays for each dollar of sales.